IL-23

Phase 1 data shows Ebdarokimab (IL12/23i) safe and well tolerated in moderate to severe plaque psoriasis patients. Abs 0752 #ACR22 @RheumNow https://t.co/QqTE4WJtDa https://t.co/eMaEurZAr0

Links:

A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics an…

Dr. Rachel Tate @uptoTate( View Tweet )

Nov 13, 2022

Industry Abstract Previews of ACR 2022
Save

Nov 11, 2022

The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do list. In the least, you should be familiar with the names and objectives of some of these studies as

TB.EMimage.CDC_.jpg

2022 EULAR Recommendations for Screening and Prophylaxis of Chronic and Opportunistic Infections
Save

Nov 07, 2022

A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).

Update to Axial Spondyloarthritis Guidance
Save

MedPage Today

Oct 26, 2022

EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.

The revision included 15 recommendations in total. Of these, 11 either remained the same from earlier editions or involved minor wording

Follow us for real time coverage #ACR2022 https://t.co/5CBdiKWdKM

Dr. John Cush @RheumNow( View Tweet )

Oct 21, 2022

Rheumatology Salaries and Career Choices A recent Doximity report shows how rheumatology salaries increase by years in practice. Rheumatologists tend to earn their highest salaries after gaining 30-39 years of experience. https://t.co/wxWQruIlu9 https://t.co/gUsIffoHn6

Links:

https://bit.ly/3MwyCqi

Dr. John Cush @RheumNow( View Tweet )

Oct 14, 2022

Single center use IL-23 inhibitors (Guselkumab, Tildrakizumab, Risankizumab) in 80 PsA pts shows 1 yr survival 81%, w/ mean survival 61 wks (despite 95% Rx ≥1 prior biologics). 64% had PASI ≤2 at wks 12-17 and nearly 41% w/ PsA remission https://t.co/woDXhL44d5 https://t.co/6fvjzGlMEY

Links:

https://bit.ly/3STJiBy

Dr. John Cush @RheumNow( View Tweet )

Oct 10, 2022

Record a Question or Comment... Rheums: Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/rICbSJzPbk https://t.co/VIjlR6xlwQ

Links:

https://bit.ly/3CmYUGX

Dr. John Cush @RheumNow( View Tweet )

Oct 10, 2022

RheumNow Podcast square

RheumNow Podcast – “That’s Not My Name” (10.7.2022)
Save

Oct 07, 2022

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.

Microbiome analyses of

Long term results of KEEPsAKE 1 and 2, RCTS of SKYRIZI (IL-23 inhibitor) in active #PsA pts were presented at EADV mtg in Milan. At wk 100, showed more than half of PsA patients achieved PASI 90 & ACR 20 responses. https://t.co/ZJsR0R5WNW https://t.co/2GU5aaSwDZ

Links:

https://bit.ly/3BX2B5T

Dr. John Cush @RheumNow( View Tweet )

Oct 02, 2022

Long term results of KEEPsAKE 1 and 2, RCTS of SKYRIZI (IL-23 inhibitor) in active #PsA pts were presented at EADV mtg in Milan. At wk 100, showed more than half of PsA patients achieved PASI 90 & ACR 20 responses. https://t.co/5upWNItwGy https://t.co/RMwDYVubOk

Links:

https://bit.ly/3ShIuq7

Dr. John Cush @RheumNow( View Tweet )

Sep 28, 2022

The 2022 ACR abstracts are published and posted for you. Let the Learning begin! https://t.co/ZqMAc8jV3U https://t.co/3iCGnzsPI5

Links:

https://bit.ly/3QGYEaD

Dr. John Cush @RheumNow( View Tweet )

Sep 14, 2022

Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/1aSrRsLkel https://t.co/gmh155ty6w

Links:

https://bit.ly/3ezSImE

Dr. John Cush @RheumNow( View Tweet )

Sep 08, 2022

Rheums! Do you have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/cvmbzknQqA https://t.co/6mX5eRUNuU

Links:

https://bit.ly/3wcwAVf

Dr. John Cush @RheumNow( View Tweet )

Aug 17, 2022

RheumNow Podcast square

The Great Unknowns (8.5.2022)
Save

Aug 05, 2022

Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.

521 clinically suspect arthralgia (CSA) pts were

ACR Updated Guideline on Vaccinations for Rheumatic Patients
Save

Aug 04, 2022

The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).

This guideline builds on past

Upadacitinib in non-radiographic Axial Spondyloarthritis
Save

Aug 01, 2022

The janus kinase inhibitor, upadacitinib, has been shown to significantly improve the signs and symptoms of non-radiographic axial spondyloarthritis (nr-AxSpA), extending the efficacy of UPA beyond classic ankylosing spondylitis.

The FDA has extended its indications for ustekinumab (Stelara) for use in pediatric psoriatic arthritis aged 6 years and older. Pediatric PsA makes up 6% of all pediatric inflammatory arthritis pts. https://t.co/vTM4x53n7k https://t.co/aQcuMury2k

Links:

https://prn.to/3bhRTha

Dr. John Cush @RheumNow( View Tweet )

Aug 01, 2022

Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders.https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz

Links:

https://bit.ly/3PB1kal

Dr. John Cush @RheumNow( View Tweet )

Jul 26, 2022

Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/QUTIbK3r89 https://t.co/FZcTLREida

Links:

https://bit.ly/3cu98fc

Dr. John Cush @RheumNow( View Tweet )

Jul 22, 2022

Rheumatologist Survey: What do you rely on MOST in diagnosing Still’s disease? Sxs? Labs? Both? Criteria? Fever? Vote here:https://t.co/oANKpKqJA5 https://t.co/LIjRSBHNBi

Links:

https://bit.ly/3RKy5TT

Dr. John Cush @RheumNow( View Tweet )

Jul 21, 2022

Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v 56%) at 1 year. Study was halted for lack of efficacy (but no safety concerns). https://t.co/uMY5uPPabA https://t.co/nG2RO6oEJQ

Links:

https://bit.ly/3AZ8m42

Dr. John Cush @RheumNow( View Tweet )

Jul 17, 2022

ICYMI: 2021 Rheumatology Year in Review
Save

Jul 08, 2022

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

GRAPPA,PsA,guideline

New Updated GRAPPA Psoriatic Arthritis Recommendations
Save

Jun 29, 2022

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,

FDA approved Abbvies risakizumab-rzaa (Skyrizi) as the 1st interleukin-23 inhibitor for use in adults with moderately to severely active Crohn's disease (600 mg IV at wk 0, 4, 8, &q8wk @ 360 mg SC). Approval based on ADVANCE, MOTIVATE & FORTIFY RCTs https://t.co/OMYNB1yr2R https://t.co/QMn9GWlYm9

Links:

https://bit.ly/3u342wl

Dr. John Cush @RheumNow( View Tweet )

Jun 26, 2022

×